...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.
【24h】

Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.

机译:使用全身照射和环磷酰胺进行调理,将无关的供体骨髓移植用于严重再生障碍性贫血。

获取原文
获取原文并翻译 | 示例

摘要

The outcome of unrelated donor bone marrow transplantation for aplastic anemia is inferior to that of sibling donor bone marrow transplantation because of a higher rate of transplant-related mortality (TRM), which is closely associated with the intensity of pretransplant conditioning to overcome graft rejection. We conducted a prospective trial with an intermediate to high dose of total body irradiation (TBI) in combination with a fixed dose of cyclophosphamide (120 mg/kg) to use for pretransplant conditioning for unrelated donor bone marrow transplantation in adult aplastic anemia. The number of patients who received doses of 1200, 1000, and 800 cGy of TBI were 5, 9, and 26, respectively. The corresponding probabilities of overall survival (OS) at 3 years were 40%, 44%, and 92%, respectively. The incidence of regimen-related toxicity with grade III-IV and graft rejection in the patients who received a dose of 800 cGy of TBI were 0 of 26 patients. The significant factors associated with OS were the TBIdose (800 cGy vs. >or=1000 cGy; P = .001), chronic graft-versus-host disease (less than or equal to limited vs. extensive; P = .013), the method of HLA typing for the donor-recipient matching (serologic typing vs. DNA-based typing; P = .006), and the transfusion amount before transplantation (90 units; P = .020).
机译:再生障碍性贫血的无关供体骨髓移植的结果比同胞供体骨髓移植的结果差,因为移植相关死亡率(TRM)的发生率更高,这与移植前克服移植排斥反应的条件强度密切相关。我们进行了一项前瞻性试验,将中剂量至高剂量的全身照射(TBI)与固定剂量的环磷酰胺(120 mg / kg)结合使用,用于成人再生障碍性贫血中无关供体骨髓移植的移植前调理。接受1200、1000和800 cGy TBI剂量的患者分别为5、9和26。 3年时相应的总体生存率(OS)分别为40%,44%和92%。接受800 cGy TBI剂量的患者中,与III-IV级方案相关的毒性反应和移植排斥的发生率为26例患者中的0例。与OS相关的重要因素是TBIdose(800 cGy vs。> = 1000 cGy; P = .001),慢性移植物抗宿主病(小于或等于有限vs.广泛性; P = .013),用于供体-受体匹配的HLA分型方法(血清分型与基于DNA的分型; P = .006),以及移植前的输血量(<或= 90对> 90单位; P = .020)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号